Genomic biomarkers in prostate cancer

Genomic biomarkers in prostate cancer - PMC - NCBI

In this review, we aim to give an update on the current status of liquid and tissue-based FDA-approved and CLIA-based tests available in the United States.

Prostate Cancer Tissue-Based Biomarkers - StatPearls - NCBI

The Oncotype DX Genomic Prostate Score was developed following similar commercial assays for breast and colorectal cancer. This assay is suitable for men with ...

Biomarkers & Genomic Testing - ZERO Prostate Cancer

Biomarker testing in prostate cancer looks at how certain sets of genes in the tumor interact and function. It can be performed on both biopsy tissue and on ...

The promising role of new molecular biomarkers in prostate cancer

Currently, there are a few molecular prognostic biomarkers in clinical use such as OncotypeDX Genomic Prostate Score [9], Prolaris [10], ProMark ...

Biomarkers for Prostate Cancer: From Diagnosis to Treatment - MDPI

PCA3, also known as DD3, is a prostate-specific mRNA biomarker that has promising potential for the detection of prostate cancer (PCa). Studies noted ...

Gene Expression Profiling and Protein Biomarkers for Prostate Cancer

The FDA has approved two tests for evaluation of gene expression profiles of prostate cancer as of April 2, 2019.

Genomic Testing & Biomarkers | PCFA

Genomic testing identifies changes in genes in prostate cancer tissue. ; Biomarkers are genes, protein and other cancer markers. ; Biomarker testing may be used ...

Genomic biomarkers in prostate cancer - Kornberg

In this review, we aim to give an update on the current status of liquid and tissue-based FDA-approved and CLIA-based tests available in the United States.

An Improved Prostate Cancer Biomarker Test May Help Men Avoid ...

Researchers funded by NCI have developed and validated a new prostate cancer urinary biomarker test that can help differentiate who should proceed for biopsy.

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity ...

To study the impact of standard-of-care hormonal therapies on metastatic prostate cancer (mPC) clinical genomic profiles in real-world practice.

Advances in Prostate Cancer Biomarkers and Probes

PCa is a complex disease, involving various molecular aberrations and cell changes [6]. With the development of biotechnology and genomics, more and more ...

Current and emerging tissue‐based molecular biomarkers for ...

Various tissue-based molecular biomarkers can be utilized in the diagnostic, prognostic, and predictive management of prostate cancer. According ...

Genomic Markers in Prostate Cancer Decision Making - ScienceDirect

This review summarizes the ability of genomic biomarkers to recognize men at high risk of developing PCa, discriminate clinically insignificant and aggressive ...

Genomic and Phenotypic Biomarkers for Precision Medicine ...

Prostate-specific antigen (PSA) is currently the main diagnostic and prognostic biomarker for PCa. Screening and monitoring the disease using ...

Genetic and Genomic Testing for Prostate Cancer: Beyond DNA ...

Minimally invasive circulating tumor DNA (ctDNA) tests are used to identify treatment-predictive and prognostic biomarkers in advanced prostate ...

Predictive Genomic Biomarkers of Hormonal Therapy Versus ...

Platinum Priority – Prostate Cancer. Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate ...

Incorporation of tissue-based genomic biomarkers into localized ...

Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same ...

Biomarkers for Prostate Cancer Diagnosis from Genetic Perspectives

Several molecular biomarkers can improve the diagnosis and solve the problem of the false-negative result of the biopsy. These biomarkers are ConfirmMDx, ...

A Multi-Omics-Focused Approach to Detection and Risk Stratification

Multi-omics has become a crucial tool in cancer biomarker discovery over the last decade, including for prostate cancer. This approach integrates data from ...

Prognostic Genomic Biomarkers in Patients With Localized Prostate ...

For example, the National Comprehensive Cancer Network risk groupings are largely based on only 3 clinical variables (Gleason grade, prostate- ...